# JAMA Oncology

Source: https://onco.cc/journals/jama-oncology/  
OnCo record `jama-oncology` (Journal). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

JAMA Oncology is the JAMA Network's cancer journal, publishing phase 2 trials, secondary analyses of big trials, epidemiology, health policy and drug-pricing research.

## Summary

JAMA Oncology has appeared monthly since 2015 and is strong on population-based and health-services research (the Global Burden of Disease cancer updates, cost and value analyses of new drugs, disparities), single-arm phase 2 studies, and pooled or secondary analyses of large randomised trials. Hybrid access; research articles free after 12 months. Sceptical editorial tone on surrogate endpoints and accelerated approvals.

## Fields

- Kind: Journal
- Last checked: 2026-09-09
- Also known as: JAMA Oncol; src-jama-oncology
- Publisher: American Medical Association (JAMA Network)
- Scope: clinical oncology
- Access: hybrid

## Notes

- Holds: Trials, health-services research and epidemiology with a strong methods focus. Access: Paywalled; abstracts free; some open access.

## Sources

- JAMA Network: https://jamanetwork.com

## Connected records

- key papers: [A prospective, multi-institutional, pathologist-based assessment of 4 immunohistochemistry assays for PD-L1 expression in non-small cell lung cancer](https://onco.cc/key-papers/paper-rimm-pd-l1-assay-comparison-jama-oncol-2017/), [Accuracy of gallium-68 PSMA-11 PET in localising recurrent prostate cancer: a prospective single-arm clinical trial](https://onco.cc/key-papers/paper-fendler-psma-pet-biochemical-recurrence-jama-oncol-2019/), [ACNS0332: carboplatin during radiotherapy and isotretinoin maintenance in high-risk medulloblastoma](https://onco.cc/key-papers/paper-acns0332-leary-jama-oncol-2021/), [Alliance A021501: preoperative modified FOLFIRINOX with or without hypofractionated radiotherapy for borderline resectable pancreatic cancer](https://onco.cc/key-papers/paper-alliance-a021501-mfolfirinox-radiotherapy-borderline-resectable-jama-oncol-2022/), [Analysis of plasma cell-free DNA by ultradeep sequencing in patients with stages I to III colorectal cancer](https://onco.cc/key-papers/paper-reinert-ctdna-ultradeep-sequencing-colorectal-jama-oncol-2019/), [Anlotinib for Refractory Advanced Non-Small Cell Lung Cancer in China](https://onco.cc/key-papers/paper-chen-jama-oncol/), [Assessment of molecular relapse detection in early-stage breast cancer](https://onco.cc/key-papers/paper-garcia-murillas-molecular-relapse-detection-jama-oncol-2019/), [Assessment of resistance mechanisms and clinical implications in patients with EGFR T790M-positive lung cancer and acquired resistance to osimertinib](https://onco.cc/key-papers/paper-oxnard-osimertinib-resistance-mechanisms-jama-oncol-2018/), [Association of alterations in main driver genes with outcomes of patients with resected pancreatic ductal adenocarcinoma](https://onco.cc/key-papers/paper-qian-driver-genes-outcomes-resected-pancreatic-jama-oncol-2018/), [Association of Black race with prostate cancer-specific and other-cause mortality](https://onco.cc/key-papers/paper-dess-black-race-prostate-mortality-jama-oncol-2019/), [Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer: Preplanned Secondary Analysis of the BRE12-158 Randomized Clinical Trial](https://onco.cc/key-papers/paper-radovich-ctdna-ctc-bre12-158-jama-oncol-2020/), [Association of clonal haematopoiesis in DNA repair genes with prostate cancer plasma cell-free DNA testing interference](https://onco.cc/key-papers/paper-jensen-clonal-haematopoiesis-cfdna-interference-prostate-jama-oncol-2021/), [Association of distinct mutational signatures with correlates of increased immune activity in pancreatic ductal adenocarcinoma](https://onco.cc/key-papers/paper-connor-mutational-signatures-immune-pancreatic-jama-oncol-2017/), [Association of high tumor mutation burden in non-small cell lung cancers with increased immune infiltration and improved clinical outcomes of PD-L1 blockade across PD-L1 expression levels](https://onco.cc/key-papers/paper-ricciuti-tmb-pd-l1-levels-jama-oncol-2022/), [Association of Maximal Extent of Resection of Contrast-Enhanced and Non-Contrast-Enhanced Tumor With Survival Within Molecular Subgroups of Patients With Newly Diagnosed Glioblastoma](https://onco.cc/key-papers/paper-molinaro-jama-oncol/), [Association of the Extent of Resection With Survival in Glioblastoma: A Systematic Review and Meta-analysis](https://onco.cc/key-papers/paper-brown-jama-oncol/), [c-TRAK TN analysis: tissue-free versus tumour-informed ctDNA assays for residual disease in early triple-negative breast cancer](https://onco.cc/key-papers/paper-ctrak-tn-tissue-free-mrd-jamaoncol-2026/), [Clinical implications of plasma-based genotyping with the delivery of personalized therapy in metastatic non-small cell lung cancer](https://onco.cc/key-papers/paper-aggarwal-plasma-genotyping-personalised-therapy-jama-oncol-2019/), [Comparison of breast cancer molecular features and survival by African and European ancestry in The Cancer Genome Atlas](https://onco.cc/key-papers/paper-huo-tcga-ancestry-breast-jama-oncol-2017/), [Dasatinib versus imatinib with chemotherapy for paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (CCCG-ALL-2015)](https://onco.cc/key-papers/paper-dasatinib-vs-imatinib-ph-positive-all-shen-jama-oncol-2020/), [Diagnostic accuracy of 68Ga-PSMA-11 PET for pelvic nodal metastasis detection prior to radical prostatectomy and pelvic lymph node dissection: a multicenter prospective phase 3 imaging trial](https://onco.cc/key-papers/paper-psma-prerp-hope-jama-oncol-2021/), [Disparity of Race Reporting and Representation in Clinical Trials Leading to Cancer Drug Approvals From 2008 to 2018](https://onco.cc/key-papers/paper-loree-jama-oncol/), [Durvalumab with or without tremelimumab for patients with metastatic pancreatic ductal adenocarcinoma: a phase 2 randomized clinical trial](https://onco.cc/key-papers/paper-oreilly-durvalumab-tremelimumab-pancreatic-jama-oncol-2019/), [Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial](https://onco.cc/key-papers/paper-nct02453282-jama-oncol-2020/), [Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial](https://onco.cc/key-papers/paper-alter-0303-jama-oncol-2018/), [Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial](https://onco.cc/key-papers/paper-reardon-jama-oncol/), [Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial](https://onco.cc/key-papers/paper-i-spy-2-jama-oncol-2020/), [Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial](https://onco.cc/key-papers/paper-nivolumab-hcc-jama-oncol-2020/), [Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Randomized Clinical Trial](https://onco.cc/key-papers/paper-nct02767804-jama-oncol-2021/), [Equecabtagene Autoleucel in Patients With Relapsed or Refractory Multiple Myeloma: The FUMANBA-1 Nonrandomized Clinical Trial](https://onco.cc/key-papers/paper-li-jama-oncol/), [Evaluation of USPSTF Lung Cancer Screening Guidelines Among African American Adult Smokers](https://onco.cc/key-papers/paper-aldrich-uspstf-screening-african-american-smokers-jama-oncol-2019/), [Examination of Low ERBB2 Protein Expression in Breast Cancer Tissue](https://onco.cc/key-papers/paper-fernandez-jama-oncol/), [First-Line Aldoxorubicin vs Doxorubicin in Metastatic or Locally Advanced Unresectable Soft-Tissue Sarcoma: A Phase 2b Randomized Clinical Trial](https://onco.cc/key-papers/paper-chawla-jama-oncol/), [Five Years of Cancer Drug Approvals: Innovation, Efficacy, and Costs](https://onco.cc/key-papers/paper-mailankody-jama-oncol/), [Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial](https://onco.cc/key-papers/paper-prodige-24-five-year-outcomes-jama-oncol-2022/), [GARNET: dostarlimab in mismatch repair-deficient recurrent or advanced endometrial cancer](https://onco.cc/key-papers/paper-garnet-dostarlimab-oaknin-jama-oncol-2020/), [Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical Trial](https://onco.cc/key-papers/paper-gap-phase2-mdacc-jama-oncol-2019/), [Germline mutation status, pathological complete response, and disease-free survival in triple-negative breast cancer: secondary analysis of the GeparSixto randomized clinical trial](https://onco.cc/key-papers/paper-hahnen-geparsixto-germline-brca-jama-oncol-2017/), [Global Retinoblastoma Presentation and Analysis by National Income Level](https://onco.cc/key-papers/paper-global-retinoblastoma-study-jama-oncol/), [KEYNOTE-062: pembrolizumab or pembrolizumab plus chemotherapy versus chemotherapy in PD-L1-positive advanced gastric cancer](https://onco.cc/key-papers/paper-keynote-062-shitara-jama-oncol-2020/), [KLASS-01: laparoscopic versus open distal gastrectomy for stage I gastric cancer, long-term survival](https://onco.cc/key-papers/paper-klass-01-kim-jama-oncol-2019/), [Magnetic Resonance Imaging-Guided vs Computed Tomography-Guided Stereotactic Body Radiotherapy for Prostate Cancer: The MIRAGE Randomized Clinical Trial](https://onco.cc/key-papers/paper-kishan-jama-oncol/), [Neoadjuvant Anbenitamab and HB1801 in ERBB2-Positive Breast Cancer: A Phase 3 Randomized Clinical Trial](https://onco.cc/key-papers/paper-nct06747338-jama-oncol-2026/), [Nivolumab and Ipilimumab Combination Treatment in Advanced Ovarian and Endometrial Clear Cell Cancers: A Nonrandomized Clinical Trial](https://onco.cc/key-papers/paper-nct04969887-jama-oncol-2025/), [Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer: The Lung-MAP S1400I Phase 3 Randomized Clinical Trial](https://onco.cc/key-papers/paper-lung-map-s1400i-jama-oncol-2021/), [Nuclear-localised androgen receptor splice variant 7 in circulating tumour cells as a predictive biomarker in castration-resistant prostate cancer](https://onco.cc/key-papers/paper-scher-nuclear-arv7-taxane-vs-arsi-jama-oncol-2018/), [Objective Response Rate Among Patients With Locally Advanced or Metastatic Sarcoma Treated With Talimogene Laherparepvec in Combination With Pembrolizumab: A Phase 2 Clinical Trial](https://onco.cc/key-papers/paper-kelly-jama-oncol/), [Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial](https://onco.cc/key-papers/paper-phillips-jama-oncol/), [Overall survival in anaplastic thyroid carcinoma 2000 to 2019: impact of targeted therapy and neoadjuvant BRAF-MEK inhibition](https://onco.cc/key-papers/paper-maniakas-neoadjuvant-braf-atc-jama-oncol-2020/), [Prevalence of germline variants in prostate cancer and implications for current genetic testing guidelines](https://onco.cc/key-papers/paper-nicolosi-germline-variants-prostate-testing-guidelines-jama-oncol-2019/), [Prevalence of microsatellite instability in prostate cancer and response to immune checkpoint blockade](https://onco.cc/key-papers/paper-abida-msi-prostate-checkpoint-blockade-jama-oncol-2019/), [Prognostic and predictive relevance of primary tumor location in patients with RAS wild-type metastatic colorectal cancer: retrospective analyses of the CRYSTAL and FIRE-3 trials](https://onco.cc/key-papers/paper-tejpar-tumour-location-crystal-fire3-jama-oncol-2017/), [Prolonged Nightly Fasting and Breast Cancer Prognosis](https://onco.cc/key-papers/paper-marinac-jama-oncol/), [Proton FLASH Radiotherapy for the Treatment of Symptomatic Bone Metastases: The FAST-01 Nonrandomized Trial](https://onco.cc/key-papers/paper-mascia-jama-oncol/), [Rates of Guideline-Concordant Surgery and Adjuvant Chemotherapy Among Patients With Early-Stage Lung Cancer in the US ALCHEMIST Study (Alliance A151216)](https://onco.cc/key-papers/paper-alchemist-jama-oncol-2022/), [Ribociclib Plus Endocrine Therapy in Hormone Receptor-Positive/ERBB2-Negative Early Breast Cancer: 4-Year Outcomes From the NATALEE Randomized Clinical Trial](https://onco.cc/key-papers/paper-natalee-jama-oncol-2025-update/), [Tepotinib Treatment in Patients With MET Exon 14-Skipping Non-Small Cell Lung Cancer: Long-term Follow-up of the VISION Phase 2 Nonrandomized Clinical Trial](https://onco.cc/key-papers/paper-nct02864992-jama-oncol-2023-update/), [The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial](https://onco.cc/key-papers/paper-nct02107703-jama-oncol-2020-update/), [Toca 5: a virus plus a prodrug in recurrent brain cancer, tested properly, and it did not work](https://onco.cc/key-papers/paper-cloughesy-toca5-glioma-jamaoncol-2020/), [Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy](https://onco.cc/key-papers/paper-hernandez-jama-oncol/), [Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Phase 2 Clinical Trial](https://onco.cc/key-papers/paper-murphy-jama-oncol/), [Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer: A Phase 1/2 Open-label Nonrandomized Clinical Trial](https://onco.cc/key-papers/paper-nct02716116-jama-oncol-2021/), [VE-BASKET: vemurafenib for BRAF V600-mutant Erdheim-Chester disease and Langerhans cell histiocytosis](https://onco.cc/key-papers/paper-ve-basket-vemurafenib-erdheim-chester-lch-jama-oncol-2018/)
- people: [Amar U. Kishan](https://onco.cc/people/amar-kishan/), [C. Ola Landgren](https://onco.cc/people/ola-landgren/), [Charu Aggarwal](https://onco.cc/people/charu-aggarwal/), [Deborah Watkins Bruner](https://onco.cc/people/deborah-bruner/), [Han-Kwang Yang](https://onco.cc/people/han-kwang-yang/), [Howard I. Scher](https://onco.cc/people/howard-scher/)

---
JSON: https://onco.cc/api/v1/entities/jama-oncology.json